

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8230757

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	ABBVIE DEUTSCHLAND GMBH & CO. KG	10/16/2018
RECEIVING PARTY DATA		
Name:	ABBVIE INC.	
Street Address:	1 NORTH WAUKEGAN ROAD	
City:	NORTH CHICAGO	
State/Country:	ILLINOIS	
Postal Code:	60064	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	18329980
CORRESPONDENCE DATA		
Fax Number:	(857)302-6843	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	857-287-3100	
Email:	Maureen.Tierney@wbd-us.com	
Correspondent Name:	WOMBLE BOND DICKINSON (US) LLP	
Address Line 1:	INDEPENDENCE WHARF	
Address Line 2:	470 ATLANTIC AVENUE	
Address Line 4:	BOSTON, MASSACHUSETTS 02210	
ATTORNEY DOCKET NUMBER:	ABV12089USD4T1	
NAME OF SUBMITTER:	MAUREEN TIERNEY	
SIGNATURE:	/Maureen Tierney/	
DATE SIGNED:	10/19/2023	
Total Attachments: 4		
source=Assignment_AbbVie GmbH to AbbVie#page2.tif		
source=Assignment_AbbVie GmbH to AbbVie#page3.tif		
source=Assignment_AbbVie GmbH to AbbVie#page4.tif		
source=Assignment_AbbVie GmbH to AbbVie#page5.tif		

ASSIGNMENT

AbbVie Deutschland GmbH & Co. KG, a corporation organized and existing under the laws of Germany having a place of business at Mainzer Str. 81, 65189 Wiesbaden, Germany

Hereinafter the "Assignor", has made certain new and useful inventions as described in the patents and patent applications set forth on Schedule A attached hereto.

WHEREAS, AbbVie Inc., a corporation organized and existing under the laws of Delaware, USA, having a place of business at 1 North Waukegan Road, North Chicago, Illinois 60064, hereinafter the "Assignee", desires to acquire the entire right, title and interest in and to the inventions and the patent application(s) identified in Schedule A, and all patents, foreign and domestic, which may be obtained for said inventions, and Assignor desires to assign such rights to AbbVie Inc., as set forth below;

NOW, THEREFORE, in exchange for valuable and legally sufficient consideration, the receipt of which is hereby acknowledged:

1. The Assignor has sold, conveyed, assigned and transferred, and by these presents do sell, convey, assign and transfer, to the Assignee its entire right, title and interest for the United States and all other jurisdictions in and to the inventions and the patent application(s) identified above, and any patents that may issue for said inventions, together with all patent applications, patents, utility models and designs therefore, including without limitation all continuations, divisions, renewals, revivals, reissues, reexaminations, extensions, supplementary protection certificates, and any substitute applications thereof, including the full right to claim all benefits and priority rights thereto under any applicable convention or treaty including without limitation the Paris Convention, and all rights of action arising from the foregoing, including without limitation all claims for damages by reason of present, past and future infringement or violation of the foregoing and all present, past and future rights to sue and collect damages or seek injunctive relief for any such infringement or violation of the foregoing, in each case, to have and to hold for sole and exclusive use and benefit of the Assignee, its successors and assigns.


2. The Assignor hereby covenants and agrees that Assignor has the full right to convey the interests granted by this Assignment; and that the Assignor will assist the Assignee (including prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by Assignee) in the prosecution of the patent applications identified in Schedule A, in the making and prosecution of any other applications that the Assignee may elect to make covering the inventions identified in Schedule A, in vesting in the Assignee with exclusive title in and to all such other patent applications and patents, in the prosecution of any interference which may arise involving said invention, or


any such patent application or patent, and in assisting Assignee in the defense and enforcement of any rights arising out of such patent application or patent, or this Assignment; and that the Assignor will execute and deliver to the Assignee any and all additional papers which may be requested by the Assignee to carry out the terms of this Assignment.

3. The terms and covenants of this Assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor and its respective heirs, legal representatives and assigns.

IN WITNESS WHEREOF, the Assignor executes this Assignment.

AbbVie Deutschland GmbH & Co. KG


ppa. Dr. Stephan Bensiek


ppa. Dr. Claudia Gonnermann

Senior Authorized Officers


Date

The Assignee accepts this Assignment.

AbbVie Inc.


Johanna Corbin
Assistant Secretary


Date

Schedule A

Country	Application Number	Application Date	Patent Number	Grant Date	Case Ref Number
United States	62/242,797	10/16/2015			ABV12089USL1
United States	62/267,672	12/15/2015			ABV12089USL2
United States	62/301,537	2/29/2016			ABV12089USL3
United States	62/352,380	6/20/2016			ABV12089USL4
United States	15/295,561	10/17/2016			ABV12089USO1
United States	15/682,451	8/21/2017	9,879,018	1/30/2018	ABV12089USC1
United States	15/682,457	8/21/2017	9,879,019	1/30/2018	ABV12089USC2
United States	15/803,538	11/3/2017	9,951,080	4/24/2018	ABV12089USC3
United States	15/857,892	12/29/2017	9,963,459	5/8/2018	ABV12089USC4
United States	15/891,012	2/7/2018			ABV12089USC5
United States	15/891,306	2/7/2018	10,017,517	7/10/2018	ABV12089USC6
United States	15/908,347	2/28/2018			ABV12089USC7
United States	15/945,225	4/4/2018			ABV12089USC8
United States	15/945,231	4/4/2018			ABV12089USC9
United States	15/954,039	4/16/2018			ABV12089USP1
Patent Cooperation Treaty	PCT/US2016/057372	10/17/2016			ABV12089WOO1
Australia	2016340167	10/17/2016			ABV12089AUO1
Brazil	1120180076775	10/17/2016			ABV12089BRO1
Canada	3002220	10/17/2016			ABV12089CAO1
China	201680070259.0	10/17/2016			ABV12089CNO1
Europe	16788358.6	10/17/2016			ABV12089EPO1
Israel	258654	10/17/2016			ABV12089ILO1
Japan	2018-517576	10/17/2016			ABV12089JPO1
South Korea	10-2018-7013644	10/17/2016			ABV12089KRO1
Mexico	MX/a/2018/004605	10/17/2016			ABV12089MXO1
New Zealand	741224	10/17/2016			ABV12089NZO1
Russia	2018117889	10/17/2016			ABV12089RUO1
Singapore	11201802990R	10/17/2016			ABV12089SGO1
South Africa	2018/02938	10/17/2016			ABV12089ZAO1